Correlation of NT-proBNP levels and cardiac iron concentration in patients with transfusion-dependent thalassemia major

Blood Cells, Molecules, and Diseases

Volumn 50, Issue 1, 2013, Pages 20-24

  Delaporta, Polyxeni ^a   Kattamis, Antonios ^a   Apostolakou, Filia ^b   Boiu, Sorina ^a   Bartzeliotou, Anastasia ^b   Tsoukas, Evangelos ^b   Papassotiriou, Ioannis ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Cardiac iron concentration; Heart failure; NT proBNP; Thalassemia major

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; FEMALE; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BLOOD TRANSFUSION; ECHO-PLANAR IMAGING; FEMALE; HEMOSIDEROSIS; HUMANS; IRON; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84869879893     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2012.09.002     Document Type: Article

References (33)

1. Hershko C. Iron loading and its clinical implications. Am. J. Hematol. 2007, 82:1147-1148.
2. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
3. Kremastinos D.T., Tiniakos G., Theodorakis G.N., Katritsis D.G., Toutouzas P.K. Myocarditis in beta-thalassemia major, a cause of heart failure. Circulation 1995, 91:66-71.
4. Kremastinos D.T., Flevari P., Spyropoulou M., Vrettou H., Tsiapras D., Stavropoulos-Giokas C.G. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. Circulation 1999, 100:2074-2078.
5. Economou-Petersen E., Aessopos A., Kladi A., Flevari P., Karabatsos F., Fragodimitri C., Nicolaidis P., Vrettou H., Vassilopoulos D., Karagiorga-Lagana M., Kremastinos D.T., Petersen M.B. Apolipoprotein E epsilon-4 allele as a genetic risk factor for left ventricular failure in homozygous betathalassemia. Blood 1998, 92:3455-3459.
6. Hahalis G., Alexopoulos D., Kremastinos D.T., Zoumbos N.C. Heart failure in β-thalassemia syndromes: a decade of progress. Am. J. Med. 2005, 118:957-967.
7. Sonakul D., Thakerngpol K., Pacharee P. Cardiac pathology in 76 thalassemic patients. Birth Defects Orig. Artic. Ser. 1988, 23:177-191.
8. Ohene-Frempong K., Schwartz E. Clinical features of thalassemia. Pediatr. Clin. North Am. 1980, 27:403-420.
9. Anderson L.J., Holden S., Davis B., Prescott E., Charrier C.C., Bunce N.H., Firmin D.N., Wonke B., Porter J., Walker J.M., Pennell D.J. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 2001, 23:2171-2179.
10. Kremastinos D.T., Tsiapras D.P., Tsetsos G.A., Rentoukas E.I., Vretou H.P., Toutouzas P.K. Left ventricular diastolic Doppler characteristics in beta thalassemia major. Circulation 1993, 88:1127-1135.
11. Sagnella G.A. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann. Clin. Biochem. 2001, 38:83-93.
12. Tschöpe C., Kasner M., Westermann D., Gaub R., Poller W.C., Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur. Heart J. 2005, 26:2277-2284.
13. Van Kimmenade R.R., Januzzi J.L. Emerging biomarkers in heart failure. Clin. Chem. 2012, 58:127-138.
14. Carpenter J.P., He T., Kirk P., Roughton M., Anderson L.J., de Noronha S.V., Sheppard M.N., Porter J.B., Walker J.M., Wood J.C., Galanello R., Forni G., Catani G., Matta G., Fucharoen S., Fleming A., House M.J., Black G., Firmin D.N., St Pierre T.G., Pennell D.J. On T2* magnetic resonance and cardiac iron. Circulation 2011, 123:1519-1528.
15. Spirito P., Lupi G., Melevendi C., Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990, 82:88-94.
16. Kremastinos D.T., Tsetsos G.A., Tsiapras D.P., Karavolias G.K., Ladis V.A., Kattamis C.A. Heart failure in beta-thalassemia: a 5-year follow-up study. Am. J. Med. 2001, 111:349-354.
17. Mavrogeni S.I., Gotsis E.D., Markussis V., Tsekos N., Politis C., Vretou E., Kermastinos D. T2 relaxation time study of iron overload in b-thalassemia. MAGMA 1998, 6:7-12.
18. Anderson L.J., Holden S., Davis B., Prescott E., Charrier C.C., Bunce N.H., Firmin D.N., Wonke B., Porter J., Walker J.M., Pennell D.J. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 2001, 22:2171-2179.
19. Chouliaras G.L., Kattamis A., Berdoukas V., Gotsis E.D., Mavrogeni S., Ladis V. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. Br. J. Haematol. 2010, 151:397-401.
20. Daniels L., Maisel A. Natriuretic peptides. J. Am. Coll. Cardiol. 2007, 50:2357-2368.
21. Shimizu H., Masuta K., Aono K., Asada H., Sasakura K., Tamaki M., Sugita K., Yamada K. Molecular forms of human brain natriuretic peptide in plasma. Clin. Chim. Acta 2002, 316:129-135.
22. Mueller T., Gegenhuber A., Poelz W., Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005, 91:606-612.
23. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., Wolf P.A., Vasan R.S. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 2004, 350:655-663.
24. Richards M., Nicholls M.G., Espiner E.A., Lainchbury J.G., Troughton R.W., Elliott J., Frampton C.M., Crozier I.G., Yandle T.G., Doughty R., MacMahon S., Sharpe N. Christchurch Cardioendocrine Research Group; Australia-New Zealand Heart Failure Group, comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J. Am. Coll. Cardiol. 2006, 47:52-60.
25. Kremastinos D.T., Tsiapras D.P., Kostopoulou A.G., Hamodraka E.S., Chaidaroglou A.S., Kapsali E.D. NT-proBNP levels and diastolic dysfunction in β-thalassaemia major patients. Eur. J. Heart Fail. 2007, 9:531-536.
26. Kremastinos D.T., Hamodraka E., Parissis J., Tsiapras D., Dima K., Maisel A. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in β-thalassemia major. Am. Heart J. 2010, 159:68-74.
27. Balkan C., Tuluce Y., Basol G., Tuluce K., Ay Y., Karapinar D.Y., Gurgun C., Bayindir O., Kavakli K. Relation between NT-proBNP levels, iron overload and early stage of myocardial dysfunction in β-thalassemia major patients. Echocardiography 2012, 29:318-325.
28. Nikolidakis S., Flessa C., Nikolaou N., Gotsis E.D., Koutouzis M., Polyhronaki E., Vrettou E., Kyriakides Z.S. Brain natriuretic peptide as marker of myocardial iron load in β-thalassemia. Int. J. Cardiol. 2007, 118:408-409.
29. Isma'eel H., Chafic A.H., Rassi F.E., Inati A., Koussa S., Daher R., Gharzuddin W., Alam S., Taher A. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am. J. Cardiol. 2008, 102:363-367.
30. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. Emerging Risk Factors Collaboration.
31. Hershko C., Graham G., Bates G.W., Rachmilewitz E.A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 1978, 40:255-263.
32. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 2003, 9:1187-1194.
33. Piga A., Longo F., Duca L., Roggero S., Vinciguerra T., Calabrese R., Hershko C., Cappellini M.D. High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol. 2009, 84:29-33.